XML 76 R20.htm IDEA: XBRL DOCUMENT v3.19.3
Note 14 - Stockholders' Equity
9 Months Ended
Sep. 30, 2019
Notes to Financial Statements  
Stockholders' Equity Note Disclosure [Text Block]
14.
STOCKHOLDERS’ EQUITY
 
Preferred Stock
 
Within the limits and restrictions provided in the Company’s Certificate of Incorporation, the Board of Directors has the authority, without further action by the shareholders, to issue up to
5,000,000
shares of preferred stock,
$.0001
par value per share, in
one
or more series, and to fix, as to any such series, any dividend rate, redemption price, preference on liquidation or dissolution, sinking fund terms, conversion rights, voting rights, and any other preference or special rights and qualifications. As of
September 30, 2019,
100,000
shares of preferred stock have been designated as Series A-
1
Convertible Preferred Stock ("Series A-
1
Stock"), of which
90,000
were issued in
2015
and
0
remain outstanding, and
105,000
shares of preferred stock have been designated as Series B-
1
Convertible Preferred Stock ("Series B-
1
Stock"), of which
105,000
were issued in
2015
and
0
remain outstanding.
 
Series A-
1
Convertible Preferred Stock
  
On
October 22
and
29,
2015,
the Company issued
84,500
shares of Series A-
1
Stock at a purchase price of
$100.00
per share, for aggregate gross proceeds of
$8,450,000.
On
November 11, 2015,
5,500
additional shares of Series A-
1
Stock were issued at a purchase price of
$100.00
per share, for gross cash proceeds of
$550,000.
 
Between
September 22, 2017
and
May 31, 2018,
the holder of the Series A-
1
Stock converted all shares of Series A-
1
Stock into an aggregate of
2,500,000
shares of common stock and purchased an aggregate of
248,893
shares of common stock in consideration of the conversion of
$896,015
of accrued dividends payable on the Series A-
1
Stock.
 
As a result of the forgoing conversions, as of
September 30, 2019
there are
no
longer any issued and outstanding shares of Series A-
1
Stock.
 
Overall balances and conversion of Series A-
1
Stock and accrued dividends into common stock has been as follows:
 
   
Series A-1
   
Accrued
Dividends
 
                 
Balance – January 1, 2017
   
90,000
    $
270,000
 
Accrual of dividends – Q1 2017
   
-
     
135,000
 
Accrual of dividends – Q2 2017
   
-
     
135,000
 
Accrual of dividends – Q3 2017
   
-
     
135,000
 
Conversion into common stock – September 2017
   
-
     
(540,000
)
Conversion into common stock – October 2017
   
(27,404
)
   
-
 
Accrual of dividends – Q4 2017
   
-
     
101,658
 
Balance – December 31, 2017
   
62,596
    $
236,658
 
Accrual of dividends – Q1 2018
   
-
     
93,894
 
Conversion into common stock – April 2018
   
(39,088
)
   
(330,552
)
Accrual of dividends – Q2 2018 (until final conversion)
   
-
     
25,463
 
Conversion into common stock – May 2018
   
(23,508
)
   
(25,463
)
Balance – December 31, 2018
   
-
    $
-
 
 
Series B-
1
Convertible Preferred Stock
 
On
November 11, 2015,
the Company issued
105,000
shares of Series B-
1
Stock at a purchase price of
$100.00
per share, for gross proceeds of
$10,500,000.
  
 
Between
March 23, 2018
and
May 23, 2018,
holders of shares of Series B-
1
Stock converted all shares of Series B-
1
Stock into an aggregate of
2,916,668
shares of common stock and purchased an aggregate of
131,229
shares of common stock in consideration of the conversion of
$472,426
of accrued dividends payable on the Series B-
1
Stock.
 
As a result of the forgoing conversions, as of
September 30, 2019
there are
no
longer any issued and outstanding shares of Series B-
1
Stock.
 
Overall balances and conversion of Series B-
1
Stock and accrued dividends into common stock has been as follows:
 
   
Series B-1
   
Accrued
Dividends
 
                 
Balance – January 1, 2017
   
105,000
    $
131,250
 
Accrual of dividends – Q1 2017
   
-
     
65,625
 
Accrual of dividends – Q2 2017
   
-
     
65,625
 
Accrual of dividends – Q3 2017
   
-
     
65,625
 
Accrual of dividends – Q4 2017
   
-
     
65,625
 
Balance – December 31, 2017
   
105,000
     
393,750
 
Conversion into common stock – March 2018
   
(60,420
)
   
(417,084
)
Accrual of dividends – Q1 2018
   
-
     
62,268
 
Accrual of dividends – Q2 2018 (until final conversion)
   
-
     
16,408
 
Conversion into common stock – May 2018
   
(44,580
)
   
(55,342
)
Balance – December 31, 2018
   
-
    $
-
 
  
 
Common Stock
 
On
March 21
and
28,
2019,
the Company issued 
13,820
 shares of common stock to its directors in payment of board and board committee fees valued at
$16,506.
 
 
On
May 14, 2019,
the Company issued
4,235
shares of common stock to its directors in payment of board and board committee fees, valued at
$5,505.
 
On
August 8
and
14,
2019,
the Company issued 
6,111
 shares of common stock to its directors in payment of board and board committee fees valued at
$6,501.
 
 
See Note
11
for common stock issued as commitment fees for notes payable in for the
three
and
nine
months ending
September 30, 2019. 
 
Securities Purchase Agreement dated
November 13, 2014
 
Pursuant to a Securities Purchase Agreement, dated
November 13, 2014,
by and between the Company and a number of private and institutional investors, the Company issued to certain private investors
664,584
shares of common stock and warrants to purchase an additional
996,877
shares of common stock for aggregate gross proceeds of
$1,595,000.
 
The warrants have a term of
five
years and an initial exercise price of
$3.60
per share, and have been fully exercisable since
February 2015.
The warrants have customary anti-dilution protections including a “full ratchet” anti-dilution adjustment provision which are triggered in the event the Company sells or grants any additional shares of common stock, options, warrants or other securities that are convertible into common stock at a price lower than
$3.60
per share, The anti-dilution adjustment provision is
not
triggered by certain “exempt issuances” which among other issuances, includes the issuance of shares of common stock, options or other securities to officers, employees, directors, consultants or service providers.
 
On
August 24, 2018
the Company issued Common Stock and Warrants to investors at a purchase price of
$1.50
per unit which triggered the anti-dilution protection provision under this Securities Purchase Agreement. As a result, the total number of outstanding and fully vested warrants was increased from
996,877
to
2,392,502,
and the exercise price was reduced from
$3.60
to
$1.50
per share. The Company recognized a non-cash deemed dividend of
$1,288,139
in
2018
in connection with these adjustments.
 
Securities Purchase Agreement dated
September 23, 2015
 
On 
September 23, 2015, 
the Company issued a warrant to purchase 
69,445
 shares of common stock in connection with the issuance of a promissory note. The warrants are immediately exercisable at an initial exercise price of 
$3.60
per share and have a term of 
five
 years. 
 
The warrants have customary anti-dilution protections including a "full ratchet" anti-dilution adjustment provision which are triggered in the event the Company sells or
 
grants any additional shares of common stock, options, warrants or other securities that are convertible into common stock at a price lower than 
$3.60
 per share. The anti-dilution adjustment provision is 
not
 triggered by certain "exempt issuances" which among other issuances, includes the issuance of shares of common stock, options or other securities to officers, employees, directors, consultants or service providers.
 
On
August 24, 2018
the Company issued Common Stock and Warrants to the investors at a purchase price of
$1.50
per unit which triggered the anti-dilution protection provision under this Securities Purchase Agreement. As a result, the total number of outstanding and fully vested warrants was increased from
69,445
to
166,668,
and the exercise price was reduced from
$3.60
to
$1.50
per share. The Company recognized a non-cash deemed dividend of
$140,827
in
2018
in connection with these adjustments. 
 
Issuances of Stock Options
 
4,000
options were granted during the quarter ended
September 30, 2019. 
The options have a
three
year vesting period,
seven
year term, and exercise price of
$1.13.
  The fair value of the options at date of issuance was estimated on the date of grant at
$3,956
using the Black-Scholes option-pricing model with the following assumptions: risk free interest rate:
1.55%,
expected life of options in years:
4.5,
expected dividends:
0,
volatility of stock price:
83%.